Intensive combined chemotherapy and radiotherapy in patients with nonresectable bronchogenic carcinoma.
D000230:Adenocarcinoma / Q000628:therapy; D000505:Alopecia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001344:Autopsy; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000628:therapy; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D003556:Cystitis / Q000139:chemically induced; D003609:Dactinomycin / Q000627:therapeutic use; D003967:Diarrhea / Q000139:chemically induced; D005069:Evaluation Studies as Topic; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008169:Lung Abscess / Q000139:chemically induced; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D010292:Paresthesia / Q000139:chemically induced; D011878:Radiotherapy / Q000009:adverse effects; D018805:Sepsis / Q000139:chemically induced; D013280:Stomatitis / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D003609:Dactinomycin; D014750:Vincristine; D003520:Cyclophosphamide; D008727:Methotrexate